News >

Scarcity of Actionable Oncogenes Should Not Preclude Testing in Breast Cancer

Andrew D. Smith
Published: Wednesday, Mar 21, 2018

Jeffrey Weitzel, MD

Jeffrey Weitzel, MD
There are many unanswered questions about oncogenes. The practical understanding of these is limited to a handful of genes such as BRCA1/2 and PI3CA. However, broad genetic assays typically yield an amount of data that dwarfs the actionable oncogene subset, based on concrete medical and scientific knowledge. It might be tempting, therefore, to skip the sort of germline DNA test that maps more than a dozen such genes—tempting but, according to leading experts in the field, unwise. Although much remains unknown about many mutations and test results rarely clarify the need for any particular response, panel testing has already demonstrated its cost value, which continues to increase every day. Each new paper has the potential to transform today’s obscure results into tomorrow’s actionable intelligence.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication